Nova Mentis Life Science Corp.
Nova Mentis Autism Clinical Study
Nova Mentis aims to recruit at least 300 participants across the U.S. and Canada to participate in our US-based Observational Study, NM101: Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS).
This is a large-scale effort to examine the dynamic roles of microbiota, serotonin signaling and the immune system in gut and brain development of ASD and FXS, particularly as these forces work together to manifest classic behavioural symptoms.
We’re looking for 200+ participants with diagnosed ASD or FXS and 100+ neurotypical controls, including pre-symptomatic/undiagnosed children under age 5. Participants will be asked to provide samples of cheek cells, urine, finger/toe-prick blood and feces, which will be used to quantify serotonin levels and related cell signaling pathways, as well as evaluate commensal bacterial species and their function in the gut. Samples will be compared with those from age-matched neurotypical controls.
To express interest in participating in the study, please register your contact information below. For more information about the study, please email email@example.com
or call 1-888-505-NOVA.
* indicates required